Can You Administer 1 mL of Kenalog in the Deltoid?
No, the deltoid should be avoided for intramuscular Kenalog (triamcinolone acetonide) injection due to a significantly higher incidence of local atrophy at this site. The FDA drug label explicitly states that "due to the significantly higher incidence of local atrophy when the material is injected into the deltoid area, this injection site should be avoided in favor of the gluteal area" 1.
Recommended Injection Site and Technique
The gluteal area is the preferred site for intramuscular Kenalog administration 1. When administering intramuscular corticosteroids:
- Deep intramuscular injection is essential - unless given deeply, local atrophy is likely to occur 1
- The gluteal muscle provides adequate tissue depth and lower risk of atrophy compared to the deltoid
- A 1 mL volume can be safely administered intramuscularly when proper technique is used in the appropriate site
Important Safety Considerations
Why the Deltoid is Problematic
The deltoid muscle has less subcutaneous tissue and muscle mass compared to the gluteal area, making it more susceptible to:
- Local tissue atrophy (the most significant concern) 1
- Inadequate depth of injection
- Visible cosmetic complications
Proper Administration Guidelines
When Kenalog must be given intramuscularly 1:
- Use the gluteal area as the primary injection site
- Ensure deep intramuscular placement to minimize atrophy risk
- Kenalog-40 is a suspension and should never be given intravenously
- This is a long-acting preparation not suitable for acute stress situations
Context Matters: Other Routes of Administration
It's worth noting that for other medications and vaccines, the deltoid is often appropriate:
- Standard vaccines and allergen immunotherapy can be given in the deltoid 2, 3, 4
- For these medications, the deltoid is actually preferred in adults and older children 2
However, Kenalog specifically carries unique risks in the deltoid that make this site inappropriate 1.
Clinical Bottom Line
Do not inject 1 mL of Kenalog into the deltoid muscle. Choose the gluteal area instead to minimize the risk of local atrophy, which occurs significantly more frequently in the deltoid region. This is a clear contraindication based on the FDA drug label and represents a critical safety consideration for this specific corticosteroid formulation 1.